American Journal of Drug Delivery and Therapeutics Open Access

  • ISSN: 2349-7211
  • Journal h-index: 6
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Reach us +32 25889658

Perspective - (2023) Volume 10, Issue 2

RNA-Based Therapeutics: Pioneering a New Era of Personalized Medicine
Christopher Jones*
Department of Pharmaceutical, University of British Columbia, Canada
*Correspondence: Christopher Jones, Department of Pharmaceutical, University of British Columbia, Canada, Email:

Received: 31-May-2023, Manuscript No. ipadt-23-17116; Editor assigned: 02-Jun-2023, Pre QC No. ipadt-23-17116 (PQ); Reviewed: 16-Jun-2023, QC No. ipadt-23-17116; Revised: 21-Jun-2023, Manuscript No. ipadt-23-17116 (R); Published: 28-Jun-2023, DOI: 10.35841/2349-7211-10.015


RNA-based therapeutics have emerged as a revolutionary class of medical interventions, ushering in a new era of personalized medicine with the potential to transform the treatment landscape for numerous diseases. Unlike traditional pharmaceutical approaches, RNA-based therapeutics leverage the inherent biological capabilities of ribonucleic acid (RNA) molecules to target and modulate gene expression, providing a novel platform for precise and potent therapies.


This article delves into the fascinating world of RNA-based therapeutics, exploring their mechanisms of action, promising applications across various medical fields, challenges faced, and the prospects they hold for delivering personalized and transformative healthcare solutions. At the heart of RNA-based therapeutics lies the understanding that RNA molecules play a pivotal role in the regulation of gene expression, orchestrating the translation of genetic information into functional proteins within cells. This fundamental biological process makes RNA an ideal target for therapeutic interventions, offering the potential to alter disease-causing pathways at their source. The two most prominent classes of RNA-based therapeutics are small interfering RNA (siRNA) and messenger RNA (mRNA). siRNA operates through the process of RNA interference (RNAi), a naturally occurring cellular mechanism that silences specific genes by degrading their mRNA counterparts. By engineering synthetic siRNA molecules complementary to the target mRNA, researchers can selectively silence disease-causing genes, effectively reducing the production of harmful proteins and curbing disease progression. Promising preclinical and clinical trials have shown encouraging results in diverse areas, including neurodegenerative disorders, infectious diseases, and certain types of cancer. In contrast, mRNA-based therapeutics represent a groundbreaking approach that exploits the natural cellular machinery for protein synthesis. Synthetic mRNA molecules carrying the genetic code for desired proteins are introduced into target cells, prompting them to produce the therapeutic proteins themselves. This technique holds immense potential for addressing diseases caused by protein deficiencies or dysfunctions, and it has garnered significant attention in the field of vaccinology. The development and successful authorization of mRNA-based vaccines against infectious diseases like COVID-19 have highlighted their agility and rapid adaptability to emerging pathogens, paving the way for future pandemic preparedness. One of the most significant advantages of RNAbased therapeutics is their potential for personalization. Traditional pharmaceuticals often employ a “one size fits all” approach, but RNA-based therapies can be tailored to individual patients based on their unique genetic makeup and disease characteristics.


In conclusion, RNA-based therapeutics hold immense promise in revolutionizing modern medicine and offering personalized treatment options for a wide range of diseases. Harnessing the power of RNA molecules to precisely manipulate gene expression represents a transformative approach that has the potential to reshape healthcare as we know it. While challenges in delivery and safety persist, ongoing research and technological advancements are rapidly pushing the boundaries of RNA-based therapies. As we venture further into this exciting frontier of medicine, the prospect of more effective, safer, and personalized treatments offers hope for a healthier and brighter future.

Citation: Jones C (2023) RNA-Based Therapeutics: Pioneering a New Era of Personalized Medicine. Am J Drug Deliv Ther. 10:015.

Copyright: © 2023 Jones C. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.